Predictors of aggressive therapy for nonmetastatic prostate carcinoma in Massachusetts from 1998 to 2002

Medical Care

Volumn 45, Issue 5, 2007, Pages 440-447

  Rose, Adam J ^a,b   Backus, Bertina M ^c   Gershman, Susan T ^c   Santos, Palmira ^d   Ash, Arlene S ^a   Battaglia, Tracy A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

^d Massachusetts Comprehensive Cancer Control Coalition   (United States)

Author keywords

African American; Cancer control; Health inequality; Health services; Prostate cancer

Indexed keywords

AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; CLINICAL PRACTICE; COMPARATIVE STUDY; ETHNOLOGY; FORECASTING; HEALTH CARE DELIVERY; HUMAN; INTENSIVE CARE; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; REGISTER; STATISTICAL MODEL; UNITED STATES; UTILIZATION REVIEW;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FORECASTING; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTENSIVE CARE; LOGISTIC MODELS; MALE; MASSACHUSETTS; MIDDLE AGED; NEOPLASM METASTASIS; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS; REGISTRIES;

EID: 34247360857     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000257144.29928.f0     Document Type: Article

References (34)

1. Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med. 1997;12:299-305.
2. Barry MJ, Fleming C, Coley CM, et al. Should medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV. Estimating the risks and benefits of an early detection program. Urology. 1995;46:445-461.
3. Patel HR, Mirsadraee S, Emberton M. The patient's dilemma: prostate cancer treatment choices. J Ural. 2003;169:828-833.
4. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407-1427.
5. Harlan L, Brawley O, Pommerenke F, et al. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 1995;13:93-100.
6. Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001;93:1864-1871.
7. Hoffman RM, Harlan LC, Klabunde CN, et al. Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. J Gen Intern Med. 2003;18:845-853.
8. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94:334-357.
9. Shavers VL, Brown ML, Potosky AL, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004;19:146-155.
10. Underwood W, De Monner S, Ubel P, et al. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol. 2004;171:1504-1507.
11. Zeliadt SB, Potosky AL, Etzioni R, et al. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004;64:1171-1176.
12. Rathore SS, Krumholz HM. Differences, disparities, and biases: clarifying racial variations in health care use. Ann Intern Med. 2004;141:635-638.
13. Stat bite: prostate cancer incidence and mortality among white and black men, 1915-2000. J Natl Cancer Inst. 2003;95:1357.
14. Denberg TD, Beaty BL, Kim FJ., et al. Marriage and ethnicity predict treatment in localized prostate carcinoma. Cancer. 2005;103:1819-1825.
15. Klabunde CN, Potosky AL, Harlan LC, et al. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998;36:1337-1348.
16. Polednak AP, Flannery JT. Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in Connecticut. Cancer. 1992;70:2152-2158.
17. Massachusetts Department of Public Health, Massachusetts Cancer Registry. Available at: http://www.mass.gov/dph/dphorg2.htm. Accessed November 30, 2006.
18. Krieger N, Chen JT, Waterman PD, et al. Race/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures - the Public Health Disparities Geocoding Project. Am J Public Health. 2003;93:1655-1671.
19. Krieger N, Chen JT, Waterman PD, et al. Painting a truer picture of US socioeconomic and racial/ethnic health inequalities: the Public Health Disparities Geocoding Project. Am J Public Health. 2005;95:312-323.
20. Understanding MassHealth Members with Disabilities. Boston, MA: Massachusetts Medicaid Policy Institute; 2004.
21. United States Census Department, 2004 American Community Survey. Available at: http://factfinder.census.gov. Accessed November 30, 2006.
22. Aschengrau A, Seage GR. Essentials of Epidemiology in Public Health. Sudbury, MA: Jones and Bartlett Publishers; 2003.
23. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston, MA: Little, Brown & Co.; 1987.
24. Eastham JA, Kattan MW. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol. 2000;163:143-145.
25. Grossfeld GD, Latini DM, Downs T, et al. Is ethnicity an independent predictor of prostate cancer recurrence alter radical prostatectomy'? J Urol. 2002;168:2510-2515.
26. Kim JA, Kuban DA, el-Mahdi AM, et al. Carcinoma of the prostate: race as a prognostic indicator in definitive radiation therapy. Radiology, 1995;194:545-549.
27. Moul JW, Connelly RR, Mooneyhan RM, et al. Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol. 1999; 162:394-397.
28. Moul JW, Sesterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995;274:1277-1281.
29. Powell IJ, Dey J, Dudley A, et al. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urology. 2002;59:907-912.
30. Underwood W III, Wei J, Rubin MA, et al. Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. Urol Oncol 2004;22:20-24.
31. Flood AB, Wennberg JE, Nease RF Jr, et al. The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team. J Gen Intern Med. 1996;11:342-349.
32. Elkin EB, Cowen ME, Cahill D, et al. Preference assessment method affects decision-analytic recommendations: a prostate cancer treatment example. Med Decis Making. 2004;24:504-510.
33. Denberg TD, Kim FJ, Flanigan RC, et al. The influence of patient race and social vulnerability on urologist treatment recommendations in localized prostate carcinoma. Med Care. 2006;44:1137-1141.
34. Shavers VL, Brown M, Klabunde CN, et al. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer. Med Care. 2004;42:239-250.